You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2: A Case Report

Versleijen, Michelle W.J. MD*; Verbist, Berit M. MD; Mulder, Jef J.S. MD; de Geus-Oei, Lioe-Fee MD*; van Herpen, Carla M.L. MD§

Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000329
Interesting Images
Abstract

Abstract: A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment 111In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. 111In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.

Author Information

From the Departments of *Nuclear Medicine, †Radiology, ‡Ear Nose and Throat, and §Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.

Received for publication April 3, 2013; revision accepted November 11, 2013.

Conflicts of interest and sources of funding: none declared.

Reprints: Michelle W.J. Versleijen, MD, MSc, PhD, Radboud University Medical Centre, Nijmegen, Department of Nuclear Medicine, Route 757, Geert Grooteplein 10, 6525 GA Nijmegen, the Netherlands. E-mail: michelleversleijen@hotmail.com.

© 2014 by Lippincott Williams & Wilkins